---
layout: default
title: Sulfur Hexafluoride
parent: 僅模型預測 (L5)
nav_order: 932
evidence_level: L5
indication_count: 10
---

# Sulfur Hexafluoride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Sulfur Hexafluoride: From Ultrasound Contrast Agent to Benign Prostatic Hyperplasia (Low-Confidence Prediction)

## One-Sentence Summary

> Sulfur hexafluoride (SF6, DrugBank DB11104) is the gas core of microbubble ultrasound contrast agents (e.g., SonoVue/Lumason) and has no established pharmacological treatment indication.
> The TxGNN model predicts a possible association with **Benign Prostatic Hyperplasia**,
> but on inspection all **3 supporting publications** are diagnostic imaging studies using SF6 as a contrast agent — none evaluate SF6 as a treatment.
> Across all 10 ranked predictions for this drug, the evidence pack itself concludes these are likely data/ontology co-occurrence artefacts rather than genuine repurposing signals.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not applicable — SF6 is used clinically as an ultrasound contrast/imaging agent, not registered for a therapeutic indication |
| Predicted New Indication | Benign Prostatic Hyperplasia (rank 34010 among all disease predictions) |
| TxGNN Prediction Score | 90.75% |
| Evidence Level | L5 (model prediction only; no treatment trials or clinical evidence) |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (Data Gap, severity: High — DG002). Based on known pharmacology, sulfur hexafluoride is an inert, poorly soluble gas encapsulated in phospholipid microbubbles and administered intravenously or intravitreally purely as a **physical contrast/tamponade medium** — it has no receptor binding, enzymatic, or systemic pharmacological activity that would plausibly treat a disease state.

The relationship between "original indication" and the predicted new indication is therefore not a genuine pharmacological repurposing case. Reviewing the underlying evidence (`repurposing_rationale.mechanistic_link`) confirms this: the TxGNN score reflects that SF6-based contrast agents are frequently *co-mentioned in the same knowledge-graph neighborhood* as prostate, vaginal, and vascular disease entities — because SF6 is commonly used to **image** these conditions (e.g., contrast-enhanced ultrasound of the prostate, transvaginal contrast sonography, peripheral arterial perfusion imaging), not because it treats them. Across all 10 predicted indications for this drug, evidence review consistently found either (a) no supporting literature/trials at all, or (b) literature that is exclusively diagnostic/imaging in nature, including one likely search mismatch (folliculitis, matched via an unrelated ophthalmic-surgery positioning paper).

Mechanistically, there is no plausible pathway by which an inert contrast gas would produce a therapeutic effect in BPH or any of the other ranked candidates. This should be treated as a case where the TxGNN score is driven by imaging-use co-occurrence rather than therapeutic association.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [20546182](https://pubmed.ncbi.nlm.nih.gov/20546182/) | 2011 | Diagnostic Imaging Study | Reproduction in Domestic Animals | Contrast-enhanced ultrasound (using SF6-type agent) used to characterize vascular perfusion in canine prostatic disease, incl. BPH — a diagnostic technique study, not a treatment trial |
| [18774354](https://pubmed.ncbi.nlm.nih.gov/18774354/) | 2008 | Diagnostic Imaging Study | Clinical Radiology | Contrast-enhanced transrectal ultrasound used to distinguish benign vs. malignant prostate nodules — imaging methodology only |
| [19212283](https://pubmed.ncbi.nlm.nih.gov/19212283/) | 2009 | Review (Imaging) | Journal de Radiologie | Review of microbubble contrast agents for tumour angiogenesis imaging; general imaging application, not BPH-specific treatment evidence |

**Note:** None of the above literature evaluates SF6 as a therapeutic intervention for BPH; all describe its established role as an ultrasound contrast agent.

---

## Singapore Market Information

Sulfur hexafluoride currently has no registered product license in Singapore (0 registrations, market status: Not Marketed). No authorization records are available to summarize.

---

## Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-interaction data are all currently unavailable — flagged as a **Blocking** data gap, DG001, preventing S1 safety pre-assessment.)

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
All 10 TxGNN-predicted indications for sulfur hexafluoride, including the top-ranked BPH prediction, are supported only by diagnostic-imaging literature or are entirely unsupported — there is no clinical trial or publication evidence of SF6 being used therapeutically for any predicted indication, and no plausible pharmacological mechanism exists for repurposing an inert contrast gas as a treatment. Evidence level is L5 across the board, and the drug is not marketed in Singapore.

**To proceed, the following is needed:**
- Confirmation from DrugBank/regulatory sources of SF6's approved use profile (contrast/tamponade agent) to formally close this candidate rather than advance it
- If reopened in future, genuine interventional (not imaging) evidence for a specific disease would be required before any S1 safety review
- Resolution of blocking data gap DG001 (label warnings/contraindications) if this or related microbubble contrast agents are evaluated again
- Resolution of DG002 (MOA) via DrugBank API query for completeness of the record
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

